Core Viewpoint - The stock of Zhaoyan New Drug has shown significant volatility, with a year-to-date increase of 70.06%, but recent declines in the short term raise concerns about its performance [1][2]. Group 1: Stock Performance - As of November 25, Zhaoyan New Drug's stock price increased by 2.02% to 28.23 CNY per share, with a trading volume of 162 million CNY and a turnover rate of 0.92%, resulting in a total market capitalization of 21.158 billion CNY [1]. - The stock has experienced a decline of 9.89% over the last five trading days, 15.48% over the last 20 days, and 14.14% over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent occurrence on September 15 [1]. Group 2: Financial Performance - For the period from January to September 2025, Zhaoyan New Drug reported a revenue of 985 million CNY, a year-on-year decrease of 26.23%, while the net profit attributable to shareholders increased by 214.79% to 80.706 million CNY [2]. - The company has distributed a total of 703 million CNY in dividends since its A-share listing, with 356 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Zhaoyan New Drug reached 96,500, an increase of 57.61% compared to the previous period [2]. - The top ten circulating shareholders include notable funds, with Huabao Zhongzheng Medical ETF holding 12.484 million shares, a decrease of 2.1693 million shares from the previous period, while new shareholders include Guangfa Small Cap Growth Mixed Fund [3].

Group 1 - The core viewpoint of the news is that Zhaoyan New Drug's stock has experienced a decline recently despite a significant increase in its price year-to-date, indicating potential volatility in the market [1][2]. - As of November 20, Zhaoyan New Drug's stock price was 29.14 yuan per share, with a market capitalization of 21.84 billion yuan and a trading volume of 1.24 billion yuan [1]. - The company has seen a year-to-date stock price increase of 75.54%, but it has declined by 13.12% in the last five trading days [1]. Group 2 - Zhaoyan New Drug operates primarily in the pharmaceutical industry, focusing on non-clinical safety evaluation services and preclinical research services, with 95.59% of its revenue coming from non-clinical research services [1][2]. - For the period from January to September 2025, Zhaoyan New Drug reported a revenue of 985 million yuan, a year-on-year decrease of 26.23%, while its net profit attributable to shareholders increased by 214.79% to 80.71 million yuan [2]. - The company has distributed a total of 703 million yuan in dividends since its A-share listing, with 356 million yuan distributed in the last three years [3]. Group 3 - As of September 30, 2025, the number of shareholders for Zhaoyan New Drug increased by 57.61% to 96,500, indicating growing interest in the stock [2]. - The top ten circulating shareholders include notable funds, with Hua Bao Zhong Zheng Medical ETF holding 12.48 million shares, a decrease of 2.17 million shares from the previous period [3]. - New shareholders include Guangfa Small Cap Growth Mixed Fund, which holds 10.28 million shares, and Guangfa Innovation Upgrade Mixed Fund, holding 9.21 million shares [3].

Core Points - The announcement details the release of part of the pledged shares by shareholder Gu Meifang, who currently holds 10,322,035 shares, representing 1.38% of the total share capital of the company [1] - After the release of the pledge, Gu Meifang has a total of 5,000,000 pledged shares, which accounts for 48.44% of her holdings [1] - The company previously announced a cash dividend of 0.40 yuan per share (before tax) and a capital reserve increase of 0.4 shares per share on July 19, 2023 [1] Summary of Key Information - As of the announcement date, Gu Meifang's pledged shares increased from 1,000,000 to 1,400,000 shares following the capital increase [1] - The notice of the release of pledged shares was received on November 17, 2025, and the company is providing specific details in this announcement [1]

Core Viewpoint - The company announced that shareholder Gu Meifang has released the pledge on 1.4 million shares, reducing the total pledged shares to 5 million, which is 48.44% of her holdings [1] Summary by Relevant Sections - **Shareholder Actions** - Gu Meifang has released the pledge on 1.4 million shares as of November 17, 2025 [1] - After the release, Gu Meifang holds a total of 10.322 million shares, representing 1.38% of the company's total share capital [1] - **Pledged Shares** - Following the release of the pledge, the total number of pledged shares held by Gu Meifang is now 5 million [1] - This represents 48.44% of her total shareholding [1]

Group 1 - The core point of the article is that Zhaoyan New Drug (SH 603127) announced the release of share pledges by Gu Meifang, who holds approximately 10.32 million shares, accounting for 1.38% of the company's total share capital [1] - After the release of the pledge, Gu Meifang has a total of 5 million shares pledged, which represents 48.44% of her holdings [1] - For the year 2024, Zhaoyan New Drug's revenue composition is projected to be 95.0% from preclinical research services, 4.95% from clinical services, and 0.04% from sales of laboratory animals and related products [1] Group 2 - As of the announcement, Zhaoyan New Drug has a market capitalization of 23.8 billion yuan [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 证券代码：603127 证券简称：昭衍新药 公告编号：2025-048 北京昭衍新药研究中心股份有限公司 关于股东部分股份解除质押的公告 2025 年 11 月 18 日 2025 年 11 月 17 日，公司接到股东顾美芳女士将其持有公司部分质押股份解除质押的 通知，现将具体情况公告如下： | 股东名称 | | | 顾美芳 | | --- | --- | --- | --- | | 本次解质股份 | | | 1,400,000 | | 占其所持股份比例 | | | 13.56% | | 占公司总股本比例 | | | 0.19% | | 解质时间 | 2025 年 | 11 月 | 14 日 | | 持股数量 | | | 10,322,035 | | 持股比例 | | | 1.38% | | 剩余被质押股份数量 | | | 5,000,000 | | 剩余被质押股份数量占其所持股份比例 | | | 48.44% | | 剩余被质押股份数量占公司总股本比例 | ...

Core Viewpoint - Zhaoyan New Drug (06127) announced the release of 1.4 million shares from pledge by shareholder Gu Meifang, reducing her pledged shares to 5 million, which is 48.44% of her total holdings [1] Summary by Relevant Sections - **Shareholder Actions** - Gu Meifang has released 1.4 million shares from pledge [1] - After the release, Gu Meifang holds a total of 10.322 million shares, representing 1.38% of the company's total share capital [1] - **Pledged Shares** - The total number of pledged shares held by Gu Meifang is now 5 million [1] - This represents 48.44% of her total shareholding [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 董事長 中 國 北 京，2025年11月17日 於 本 公 告 日 期，董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 高 大 鵬 先 生、孫雲霞女士、羅樨女士及顧靜良先生，及獨立非執行董事張帆先生、楊福全 先 生、陽 昌 雲 先 生 及 應 放 天 先 生。 证券代码：603127 证券简称：昭衍新药 公告编号：2025-048 北京昭衍新药研究中心股份有限公司 海外監管公告 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出 ...

南财智讯11月17日电，昭衍新药公告，2025年11月17日，公司接到股东顾美芳女士通知，其于2025年11 月14日将其持有公司的140.00万股股份办理了解除质押手续。本次解除质押后，顾美芳女士累计质押公 司股份数量为500.00万股，占其所持股份的48.44%。 ...

Core Points - The company, Beijing Joinn Laboratory, has announced the convening of its second extraordinary general meeting of shareholders for 2025, scheduled for December 5, 2025, at 14:30 [1] - The meeting will utilize a combination of on-site and online voting methods, with the online voting system provided by the Shanghai Stock Exchange [1][2] - Shareholders must register to attend the meeting and can delegate their voting rights to a proxy if unable to attend in person [10][11] Meeting Details - The meeting will take place at the company's conference room located in Beijing Economic and Technological Development Zone [1] - Voting will be available through the Shanghai Stock Exchange's online voting system on the same day as the meeting, with specific time slots for trading system voting and internet voting [1][2] - Shareholders holding multiple accounts can vote through any of their accounts, but must ensure that their votes do not exceed their total voting rights [4][5] Voting Procedures - The company has outlined specific procedures for shareholders participating in the online voting, including identity verification for first-time users [3][4] - There are no proposals requiring separate voting for minority investors or involving related party transactions [3] - The company will provide reminders to shareholders about the meeting and voting through SMS and other means to ensure participation [7] Attendance and Registration - Only shareholders registered with the China Securities Depository and Clearing Corporation Limited as of the close of trading on the registration date are eligible to attend [8] - Personal shareholders must present valid identification, while corporate shareholders must provide documentation proving their legal representation [10] - Registration must be completed 24 hours prior to the meeting [10]